No Data
Zhejiang Tianyu Pharmaceutical (300702.SZ): Jing Sheng Pharmaceutical's Canagliflozin Active Pharmaceutical Ingredient has passed the CDE review.
On March 21, Gelonghui reported that Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Jingsheng Pharmaceutical Co., Ltd. (referred to as "Jingsheng Pharmaceutical"), has recently passed the review by the National Medical Products Administration's Center for Drug Evaluation (referred to as "CDE") for the Active Pharmaceutical Ingredient of Canagliflozin. Canagliflozin is primarily used for the treatment of type 2 diabetes and can be used in combination with Metformin, or Metformin/sulfonylurea drugs. When blood sugar control is inadequate with Metformin alone, it can be used in conjunction with Metformin, along with diet and exercise to improve blood sugar control in adult patients with type 2 diabetes.
Zhejiang Tianyu Pharmaceutical (300702.SZ): The registration certificates for Malate Avatrombopag tablets and Tofacitinib tosylate tablets have been obtained.
On March 10, Gelonghui reported that Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary Zhejiang Nuode Pharmaceutical Co., Ltd. recently received the Drug Registration Certificate approved by the National Medical Products Administration for Avatrombopag Maleate Tablets and Edoxaban Tosilate Tablets. Avatrombopag Maleate Tablets are a platelet-stimulating receptor agonist suitable for adult patients with chronic liver disease-related thrombocytopenia undergoing elective diagnostic procedures or surgeries, as well as for chronic primary immune thrombocytopenia (ITP) patients who previously responded poorly to treatments such as Glucocorticoid and immunoglobulin.
Zhejiang Tianyu Pharmaceutical (300702.SZ): Changyi Tianyu has successfully passed the recognition as a high-tech enterprise for the first time.
On March 4th, Gllonghui reported that Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that its wholly-owned subsidiary Changyi Tianyu Pharmaceutical Co., Ltd. (referred to as "Changyi Tianyu") recently received the "High-tech Enterprise Certificate" jointly issued by the Shandong Provincial Science and Technology Department, Shandong Provincial Finance Department, and the State Taxation Administration of Shandong Provincial Taxation Bureau.
Zhejiang Tianyu Pharmaceutical (300702.SZ) passed the on-site inspection by the FDA in the USA.
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the company will be...
Tianyu Pharmaceutical Unit's Edoxaban Tosylate Passes Chinese Drug Administration's Review
Zhejiang Tianyu Pharmaceutical (300702.SZ): The Active Pharmaceutical Ingredient of Maleic Acid Avapritinib has passed the CDE review.
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the Active Pharmaceutical Ingredient for Malatopar is recently approved by the National Medical Products Administration...
Further Weakness as Zhejiang Tianyu Pharmaceutical (SZSE:300702) Drops 11% This Week, Taking Three-year Losses to 64%
